In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...

Pacira Biosciences PCRX announced that the FDA has accepted for review its supplemental new drug application (sNDA) for Exparel. The sNDA seeks to expand Exparel’s label to include a single-dose ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...

— New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures — An adductor ...